

United States Patent and Trademark Office

TED STATES DEPARTM

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/601,345	06/19/2003	Andreas Gerardus Uitterlinden	KILS121089	5017
26389	7590 11/03/2005		EXAMINER	
CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE			SALMON, KATHERINE D	
SUITE 2800	AVENUE		ART UNIT	PAPER NUMBER
SEATTLE, V	VA 98101-2347		1634	-

DATE MAILED: 11/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
Office Action Summary		10/601,345	UITTERLINDEN E	ET AL.
		Examiner	Art Unit	
		Katherine Salmon	1634	
Period fo	- The MAILING DATE of this communication ap r Reply	pears on the cover shee	et with the correspondence ac	ddress
A SHO WHIC - Exten after: - If NO - Failur Any re	DRTENED STATUTORY PERIOD FOR REPL HEVER IS LONGER, FROM THE MAILING Estons of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period to to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailing different term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMU 136(a). In no event, however, m will apply and will expire SIX (6) e, cause the application to becor	JNICATION. ay a reply be timely filed MONTHS from the mailing date of this one ABANDONED (35 U.S.C. § 133).	
Status				
2a) <u></u>	Responsive to communication(s) filed on 19. This action is FINAL . 2b) This Since this application is in condition for allowed closed in accordance with the practice under	s action is non-final. ance except for formal r	-	e merits is
Dispositi	on of Claims			
5) 6) 7)	Claim(s) <u>1-30</u> is/are pending in the application 4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-30</u> are subject to restriction and/or	awn from consideration		
Applicati	on Papers			
9) 🔲 .	The specification is objected to by the Examin	er.		
10) 🔲	The drawing(s) filed on is/are: a) 🔲 ac	cepted or b) objected	d to by the Examiner.	
	Applicant may not request that any objection to the			
11) 🔲	Replacement drawing sheet(s) including the corre The oath or declaration is objected to by the E			
Priority u	inder 35 U.S.C. § 119			
12)[] a)[Acknowledgment is made of a claim for foreig All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Bures see the attached detailed Office action for a list	nts have been received nts have been received ority documents have b au (PCT Rule 17.2(a)).	in Application No een received in this Nationa	ıl Stage
2) Notice 3) Information	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/06 r No(s)/Mail Date	Pape 5) Notice	riew Summary (PTO-413) r No(s)/Mail Date e of Informal Patent Application (PT	FO-152)

Application/Control Number: 10/601,345 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-26 and 29-30, drawn to a method of determining susceptibility to a bone fracture and treating to decrease the risk of a bone fracture, classified in class 514, subclass 44.
 - II. Claims 27-28, drawn to a kit comprising nucleic acid primer molecules of estrogen receptor and vitamin D receptor genes, means for determining the presence of px haplotype and baT haplotype, and means for indicating a correlation between the presence of haplotype and risk of bone fracture, classified in class 536, subclass 24.33.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of Invention III can be used for the methods of determining susceptibility and treatment to decrease the risk of a bone fracture or the product could be used to make antisense nucleic acids for gene therapy. The search for each invention presents a serious burden, as the

Application/Control Number: 10/601,345

Art Unit: 1634

searches for each are not coextensive in scope. Art relating to the methods of determining susceptibility and treatment would not necessarily provide descriptive information for nucleic acid primer molecules for amplification of the estrogen receptor or the vitamin D receptor.

4. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Application/Control Number: 10/601,345 Page 4

Art Unit: 1634

"Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because Inventions I-III required different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/601,345 Page 5

Art Unit: 1634

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katherine Salmon whose telephone number is (571) 272-3316. The examiner can normally be reached on Monday -Friday 8AM-430PM.

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Katherine Salmon

Kathemo Solmon 10/27/05

Examiner

Art Unit 1634

10/29/05